TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03170505

Intervention type: PROCEDURE
Intervention: repairing fistula
Description: A tailored piece of Acellular Dermal Matrix or Conchal Cartilage will be placed between the oral and nasal layers for repair of a Cleft Palate.

Intervention type: PROCEDURE
Intervention: repairing fistula
Description: A tailored piece of Acellular Dermal Matrix or Conchal Cartilage will be placed between the oral and nasal layers for repair of a Cleft Palate.
Study: NCT04249206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root Canal Treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root Canal Treatment
Study: NCT02046785

Intervention type: OTHER
Group type: OTHER
Intervention: 0.9% saline solution
Description: comparing values obtained before and after administration of 500 ml of 0.9% salin
Study: NCT03629847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
Study: NCT02427373

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil ethyl ester

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil triglyceride

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: krill oil
Study: NCT03339791

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve Gastrectomy
Description: Laparoscopic Sleeve Gastrectomy. Technique: complete mobilization of the greater curvature and gastric fundus up to the angle of Hiss; stapling beginning at 3 to 4 cm away from the pylorus; bougie size 32 French; oversuture of the staple line; hiatoplasty in selected cases; routine drainage of the abdominal cavity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Bypass
Description: Laparoscopic Gastric Bypass. Technique: Pouch size 30 to 40 ml, biliopancreatic limb 70 to 100 cm, alimentary limb 100 to 120 cm, antecolic, routine closure of the mesenterial defects, routine drainage of the abdominal cavity
Study: NCT02552381

Intervention type: OTHER
Intervention: Fibrin Structure
Description: Modifications of Fibrin Structure in patients who have developed VTE in comparison with patients without VTE.

Intervention type: OTHER
Intervention: Fibrin Structure
Description: Modifications of Fibrin Structure in patients who have developed VTE in comparison with patients without VTE.

Intervention type: OTHER
Intervention: Fibrin Structure
Description: Modifications of Fibrin Structure in patients who have developed VTE in comparison with patients without VTE.
Study: NCT03645070

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multipolar and self expandable thermometer
Description: Will be evaluated if a multipolar and self expandable thermometer is superior to no probe or to single probe thermometer at prevention of esophageal thermal injury.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single probe thermometer
Description: Will be evaluated if a single probe thermometer is superior to a multipolar and self expandable thermometer or to no probe thermometer at prevention of esophageal thermal injury
Study: NCT02789111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvimopan
Description: Alviimopan 12 mg twice daily up to 15 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily up to 15 doses
Study: NCT04070456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tablet-based SDH tool
Description: A tablet-based SDH tool, which integrates responses into the EpicCare electronic health record (EHR).
Study: NCT02024828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early/Slow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early/Fast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late/Slow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late/Fast
Study: NCT00533520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days
Study: NCT01284595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] AZD8931
Description: Single 160 mg oral dose administered on Day 1
Study: NCT01199601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concentrated postpartum counseling
Description: Intrapartum testing and concentrated postpartum counseling for the female patient from a retrained provider focusing on correct breastfeeding practices, postpartum contraception, and infant vaccination.
Study: NCT00209209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: coricosteroide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-alpha
Description: cytokine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated formula Interferon-alpha 2b
Description: cytokine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy: R-CHOP
Description: immuno-chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chemotherapy: R-FC
Description: immuno-chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interferon maintenance
Description: cytokine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Description: antibody
Study: NCT02818556

Intervention type: DRUG
Group type: OTHER
Intervention: Restalyne Silk

Intervention type: DRUG
Group type: OTHER
Intervention: Restalyne Silk

Intervention type: DRUG
Group type: OTHER
Intervention: Belotero Balance
Study: NCT04241250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EAW+TS (exoskelton and transspinal stimulation)
Description: Three months of exoskeleton training followed by 6 months of transspinal stimulation.
Study: NCT01082666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous control of cuff pressure
Description: Continuous control of cuff pressure using a pneumatic device (Nosten, Leved, France)
Study: NCT01823926

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation
Description: Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure (França et al., 2006).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure (França et al., 2006).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet nebulizer
Description: Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min.
Study: NCT01082666

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual control of cuff pressure
Description: Manual control of cuff pressure is a routine practice in ICU patients
Study: NCT02429128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 14 weeks exercise training

Intervention type: OTHER
Group type: OTHER
Intervention: 14 weeks exercise training
Study: NCT01823926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The vibrating mesh nebulizer (VMN)
Description: Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
Study: NCT05553808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel was administered as IV infusion.
Study: NCT03581344

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Repetition of Re-staging
Description: Second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy if major or complete response at 7-8 weeks
Study: NCT02818556

Intervention type: DRUG
Group type: OTHER
Intervention: Belotero Balance
Study: NCT02873481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Centering Pregnancy Care plus Yoga (CPC+Y)
Description: Gentle prenatal yoga for 30 minutes at the end of the Centering Pregnancy Care session
Study: NCT04364165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard invitation to free HIV testing at mobile clinic
Description: Participants receive standard invitation to same day HIV testing at mobile clinic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: U=U messaging and invitation to free HIV testing at mobile clinic
Description: Participants receive messaging about being undetectable equals untransmittable (U=U) and invitation to same day HIV testing at mobile clinic.
Study: NCT01696474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study: NCT02521948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MANTA Vascular Closure Device
Description: The MANTA device developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
Study: NCT02742779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0310
Description: Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0310
Description: Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0310
Description: Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0310
Description: Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0310
Description: Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0310
Description: Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0310
Description: Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0310
Description: Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to GDC-0310 as single or multiple oral dose in fasted or fed state.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to GDC-0310 as single or multiple oral dose in fasted or fed state.
Study: NCT04022057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: Local anesthetic injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dextrose 5
Description: Sham Injection
Study: NCT05553808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel was administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feladilimab
Description: Feladilimab was administered as IV infusion.
Study: NCT03726034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Story Book
Description: The protocol of life story book creation is validated in Hong Kong. The life story book would contain two elements: (1) the development of the older adults over the course of his/her lifetime (i.e. from childhood to old age); and (2) the psychosocial development and ways of life of the older adults (e.g. education, marriage, career, and hobbies). The product of the intervention will be a written story with pictures or other memorabilia that are meaningful to the older adults. There is no limitation on the number of words, pages, and pictures. Four to six 60-minute scheduled sessions will be needed for the older adult and the live-in migrant caregivers to discuss and produce the lifestory book at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-selected social activities
Description: To control the possible social interaction effects on the dyadic relationship and wellbeing, the caregivers of the control group will conduct self-selected social activities with older adult at home individually for four times weekly.
Study: NCT02086357

Intervention type: PROCEDURE
Intervention: SWUE
Study: NCT01299246

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Michigan Neuropathy Screening Instrument
Description: Peripheral neurological assessment was carried out using MNSI. The diabetes nurse educators assessed five parameters on both feet and counted the total points, ranging from 0 to10: (1) Appearance of feet; if abnormal, then inspection of lower limbs for deformities was carried out; (2) Identification of foot ulceration; (3) Vibration perception of the big toe; (4) Ankle reflexes; (5) touch-pressure sensation test with a 10 g Semmes-Weinstein monofilament.
Study: NCT01556438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tabalumab
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tabalumab
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tabalumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally
Study: NCT01597544

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CISC instruction pre-operatively
Description: Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
Study: NCT01494402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961S
Description: Oral gelatine capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral HPMC capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered acetylsalicylic acid
Description: Tablet
Study: NCT00854451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole plus amoxicillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole plus amoxicillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole plus amoxicillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole plus amoxicillin
Study: NCT04094454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: special tampon with a diameter of 28mm
Description: patients will use a special tampon with extended vaginal dilatation (diameter 28mm) during radiotherapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard tampon with a diameter of 12-13mm
Description: patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
Study: NCT02734212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ending Self Stigma for PTSD
Description: Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Treatment as Usual
Description: The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
Study: NCT00167674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined short-course zidovudine/nevirapine
Description: 300 mg of ZDV was given twice daily from 34 weeks gestation until labor then every 3 hours until delivery; 200 mg of NVP was given as a single oral dose at the onset of labor; and a single 2 mg/kg (6 mg if birthweight \> 2.5 kg) oral dose of NVP suspension was administered to the infant within 72 hours of delivery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: 300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.
Study: NCT00496665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Taken orally once a day in 28-day cycles (the dose will vary)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week
Study: NCT02978274

Intervention type: DRUG
Intervention: MMF
Description: MMF withdrawal by engraftment post haplo-SCT

Intervention type: DRUG
Intervention: MMF
Description: MMF withdrawal by 2 month post haplo-SCT
Study: NCT02096653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-ray SI joint steroid injection
Description: Injection of steroid and local anesthetic into the joint cavity using fluoroscopic guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmark-guided SI steroid injection
Description: Injection of steroid into the joint area based on palpation. The injection may be inside the joint (intra-articular) or outside the joint in the ligaments (extra-articular)
Study: NCT00242112

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI Prostate
Study: NCT03680599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connection to Health for Smokers
Description: Connection to Health for Smokers includes 5 core components supported by online tools: (1) comprehensive electronic patient survey, (2) automated summary report to flag areas of difficulty (3) interactive priority setting, (4) interactive action planning, and (5) electronic text reminders and followup.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: Participants will complete a survey and receive standard one-on-one smoking cessation according to a usual care protocol delivered by health educators